Potent antiretroviral therapy initiates normalization of hypergammaglobulinemia and a decline in HIV type 1-specific antibody responses.
about
Characterising B cell numbers and memory B cells in HIV infected and uninfected Malawian adults.Persistence of HIV-1 structural proteins and glycoproteins in lymph nodes of patients under highly active antiretroviral therapy.Immunoglobulin G kappa [IgG kappa] and IgG lambda paraproteinemia in a child with AIDS and response to highly active antiretroviral therapy.Morphological and immunological changes in the skin of autopsied women with AIDS.Noninfectious X4 but not R5 human immunodeficiency virus type 1 virions inhibit humoral immune responses in human lymphoid tissue ex vivoSerologic responses to recombinant Pneumocystis jirovecii major surface glycoprotein among Ugandan patients with respiratory symptoms.B cells in early and chronic HIV infection: evidence for preservation of immune function associated with early initiation of antiretroviral therapy.B cells in HIV infection and diseaseThe influence of age, smoking, antiretroviral therapy, and esophagitis on the local immunity of the esophagus in patients with AIDS.Acquisition of host-derived CD40L by HIV-1 in vivo and its functional consequences in the B-cell compartment.Perturbations in B cell responsiveness to CD4+ T cell help in HIV-infected individualsHow can HIV-type-1-Env immunogenicity be improved to facilitate antibody-based vaccine development?Effect of highly active antiretroviral therapy on biomarkers of B-lymphocyte activation and inflammation.Suboptimal immune reconstitution in vertically HIV infected children: a view on how HIV replication and timing of HAART initiation can impact on T and B-cell compartmentDynamics of memory B-cell populations in blood, lymph nodes, and bone marrow during antiretroviral therapy and envelope boosting in simian immunodeficiency virus SIVmac251-infected rhesus macaques.Decreased survival of B cells of HIV-viremic patients mediated by altered expression of receptors of the TNF superfamily.Role of IL-21 and IL-21 receptor on B cells in HIV infection.Characterization of plasmablasts in the blood of HIV-infected viremic individuals: evidence for nonspecific immune activation.Pathogenic mechanisms of B-lymphocyte dysfunction in HIV diseaseEvolution of broadly cross-reactive HIV-1-neutralizing activity: therapy-associated decline, positive association with detectable viremia, and partial restoration of B-cell subpopulationsEnhanced FCGR2A and FCGR3A signaling by HIV viremic controller IgG.Immunoglobulin levels amongst persons with and without human immunodeficiency virus type 1 infection in Uganda and Norway.HIV-1-Mediated BAFF Secretion in Macrophages Does Not Require Endosomal TLRs, Type-I IFN, and Nef, but Depends on the Cellular Phenotype Status.Higher Transplacental Pathogen-Specific Antibody Transfer Among Pregnant Women Randomized to Triple Antiretroviral Treatment Versus Short Course Zidovudine.Early initiation of antiretroviral treatment postSIV infection does not resolve lymphoid tissue activation.Assessing immune aging in HIV-infected patientsSerum free light chains in patients with HIV infection: their association with markers of disease severity and antiretroviral use.Plasma CXCL13 but Not B Cell Frequencies in Acute HIV Infection Predicts Emergence of Cross-Neutralizing Antibodies.Antibody-dependent effector functions against HIV decline in subjects receiving antiretroviral therapy.Highly efficient neutralization by plasma antibodies from human immunodeficiency virus type-1 infected individuals on antiretroviral drug therapy.Trimethoprim-sulfamethoxazole exposure alters ex vivo function of B lymphocytes isolated from human immunodeficiency virus-infected patients receiving Zidovudine.A T2 cytokine environment may not limit T1 responses in human immunodeficiency virus patients with a favourable response to antiretroviral therapy.
P2860
Q33699375-12F61FEA-1748-482A-8B94-6E0C5E5DA40CQ34078508-29F68E32-D0E2-4772-8C31-7BE4CBFB17E7Q34143572-CD4D6CE5-389F-4F40-86B4-C684E701D478Q34381159-A54633D2-5A9B-4FC9-923C-E71E95D0E298Q34437067-45729C8A-5097-4721-B353-F2FABCF95ED9Q34531964-1E30BDB3-620A-455F-B6EA-CBC745ACA7F9Q34541705-22104EF5-731A-4DA4-9CE3-6557B5EB5A35Q34605780-1F4F6B0B-3A21-4CB8-A70F-AD4A635ACDEFQ34725060-4553CF72-5B31-4207-9172-C231CE0D5565Q34741868-9FCBA8E8-E85F-436C-9DD4-1C3E03B81D12Q35022773-49FAA368-5CA7-4034-8B09-8C8C5BCF8DBEQ35653703-63925FBF-6EB5-44AF-A4B7-2824ABFEA856Q35878906-BAB99B9C-F1E3-4037-A6C5-23578BD1E171Q35895763-5E29C010-EF66-4240-8C17-0C19B22FC316Q36397469-973B21DE-33BA-4234-9E73-0F874652DBA0Q36488962-395C90B5-9E45-4FA5-B489-86DE53A388EDQ36670538-DC5D2424-6045-454B-8B74-4DAA286623ACQ36827309-39EA10FC-DF6E-4330-B543-42ECEC3ECBD3Q37189179-DB8FB662-9F79-4BBB-B1EF-A5BD43B51D78Q37254327-00FAD565-4320-4092-8B44-01CB24DE5296Q37646897-5F7EB008-AFD3-4D79-9906-81954B3D8B86Q38882388-CAB2CB05-72B4-49F1-8416-9F64666A552DQ39027389-5A6A2FE5-95FD-494E-B3B4-7B8E66EC132DQ40073325-8FC958BD-FC06-41D2-B9D0-CD642412CD80Q40129327-D9D8A0A1-758D-49CA-9E36-347760B170A4Q41198351-9CE24900-EB88-4C90-BC61-37E3C6CB74C7Q41632306-41AD040E-238E-4322-A529-40064AEAF34EQ41699538-220CF371-9537-4DE2-9443-BDA09F3D8CD0Q42196466-B32FF9CC-F295-41A7-9DB3-8A9369ADA0A7Q42228026-FF05725F-A60E-4636-8210-09C339F4894CQ45385690-257E3276-4D47-45A2-A617-E0458FABF640Q45415273-E9A7F98D-F5F5-4F68-AC40-4909CC604A48
P2860
Potent antiretroviral therapy initiates normalization of hypergammaglobulinemia and a decline in HIV type 1-specific antibody responses.
description
2001 nî lūn-bûn
@nan
2001年の論文
@ja
2001年学术文章
@wuu
2001年学术文章
@zh-cn
2001年学术文章
@zh-hans
2001年学术文章
@zh-my
2001年学术文章
@zh-sg
2001年學術文章
@yue
2001年學術文章
@zh
2001年學術文章
@zh-hant
name
Potent antiretroviral therapy ...... 1-specific antibody responses.
@en
Potent antiretroviral therapy ...... 1-specific antibody responses.
@nl
type
label
Potent antiretroviral therapy ...... 1-specific antibody responses.
@en
Potent antiretroviral therapy ...... 1-specific antibody responses.
@nl
prefLabel
Potent antiretroviral therapy ...... 1-specific antibody responses.
@en
Potent antiretroviral therapy ...... 1-specific antibody responses.
@nl
P2093
P921
P1476
Potent antiretroviral therapy ...... 1-specific antibody responses.
@en
P2093
Goudsmit J
Hellings JA
Notermans DW
de Jong JJ
de Ronde A
P304
P356
10.1089/088922201300343681
P577
2001-07-01T00:00:00Z